';
Tags Posts tagged with "ODP"

ODP

Image by Gerd Altmann from Pixabay

The Office of Developmental Program’s (ODP) Technology Taskforce has published its Technology Today: Volume 7 January 2024 newsletter. The purpose of the newsletter is to seek out methods of supporting individuals with disabilities, family members, and providers with resources, events, and other important updates in the assistive technology world. This includes compilations of resources that support individuals through technology with software, hardware, funding, programs, and information as well as recommendations for starting your supportive technology journey.

Photo by Markus Winkler on Unsplash

Message from Kevin Dressler, Bureau Director, DHS, Office of Developmental Programs:

Infection Control and Vaccination Status Survey
The Office of Developmental Programs (ODP) has put together a short survey (23 questions) to gain an idea of the vaccination status of the people living in ICFs for COVID, Flu, and RSV, as well as to identify difficulties you may have or are currently experiencing with obtaining the vaccines. There is also a section within the survey discussing infection control and prevention. Please take the time to fill out the survey, as ODP will use the information to continue to look for ways to improve access and availability of vaccines and other health-related resources.

Several responded that the survey was not accessible. Participant restrictions have been removed this morning, so you should now be able to complete the survey here.

ICF Task Force Meeting
The next ICF Task Force meeting will be conducted in-person on April 18, from 10:00 am – 3:00 pm. We are planning to hold the meeting at the PaTTAN (Pennsylvania Training and Technical Assistance Network) building in Harrisburg. We plan to share ICF citation data from January 1, 2017 – December 31, 2023, as well as two trainings. The trainings will be “Plan of Correction Writing and Follow-up,” and training on “Active Treatment.” We will also have the DOH Long Term Care – RISE group provide a presentation on the services and supports they have to offer to ICFs. Lastly, we will have our typical updates from our finance staff, DOH, and ODP Medical Director. Please plan on attending. Updates will be provided as we get closer to the date of the meeting.

ICF Taskforce Meeting: Location
The ICF Taskforce Meeting on Thursday, April 18, 2024, will be held at the following address:

PaTTAN – Central
6340 Flank Drive
Harrisburg, PA 17112

Directions and nearby hotel accommodations can be found here.

The Office of Developmental Programs (ODP) has shared ODPANN 24-019. This announcement is directed at all ODP Service Providers who employed Direct Service Professionals (DSP) in 2023. The purpose of the announcement is to inform service providers of ODP’s preparation to open the 2023 NCI® State of the Workforce (SoTW) Survey portal. Please view the announcement and survey reference for information on completing the survey.

Secretary Val Arkoosh and leadership from the Department of Human Services (DHS) will host a webinar to discuss the proposed 2024/25 budget for the department. The briefing will take place at 10:00 am on Friday, February 9. If you are unable to attend, the briefing will be recorded and available for viewing afterwards.

Visit here to register for the briefing. DHS encourages individuals to submit questions ahead of the briefing so they can prepare as much information as possible. The Departments will follow up on any questions that they are unable to answer during the webinar.

(If the registration link above does not work, please try copying this link directly into your browser: https://events.gcc.teams.microsoft.com/event/3049c317-17f6-46ab-8396-1e5f3a370422@418e2841-0128-4dd5-9b6c-47fc5a9a1bde)

The Office of Developmental Program (ODP) has shared ODPANN 24-018. The purpose of this announcement is to inform all interested parties that rolling HCSIS data fixes will be performed starting February 8, 2024, to adjust ISPs to support the transition from Palco, Inc. to the new statewide Vendor Fiscal/Employer Agent (VF/EA) Financial Management Services (FMS) organization, Public Partnership LLC (PPL). Please view the communication for important details about the transition to PPL.

The Office of Developmental Programs (ODP) has shared ODPANN 24-015.The purpose of this communication is to provide guidance for implementing changes to assistive technology and remote supports in the amendments to the Consolidated, Community Living, Person/Family Directed Support (P/FDS) and Adult Autism Waivers. View the announcement and the forms below for details.

The Office of Developmental Programs (ODP) has shared ODPANN 24-014. The purpose of this announcement is to communicate that Temple University Harrisburg Certified Investigator Program and ODP will be facilitating Forums for Certified Investigators (CI) and others involved in the incident investigation process. This also announces the posting of Q&A documents from past CI Forums on myODP. Please view the announcement for information and details.

The Office of Developmental Programs (ODP) has shared this important announcement from the U.S. Food and Drug Administration (FDA) about a recall of two cough medicine products by Robitussin. The products are Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult. Please see the specific Lot Numbers below that are involved in the recall.  If you have one of these products with the matching Lot Number, stop use immediately and contact your health care provider.


Haleon Issues Voluntary Nationwide Recall of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult Products Due to Microbial Contamination

Summary
Company Announcement Date: January 24, 2024
FDA Publish Date: January 24, 2024
Product Type: Drugs
Reason for Announcement: Microbial Contamination
Company Name: Haleon
Brand Name: Robitussin
Product Description: Cough syrups

Haleon is voluntarily recalling eight lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult to the consumer level. The product is being recalled due to microbial contamination.

In immunocompromised individuals, the use of the affected product could potentially result in severe or life-threatening adverse events, such as fungemia or disseminated fungal infection. In non-immunocompromised consumers, the population most likely to use the product, life-threatening infections are not likely to occur. However, the occurrence of an infection that may necessitate medical intervention cannot be completely ruled out. To date, Haleon has not received any reports of adverse events related to this recall.

Robitussin Honey CF Max Day and Nighttime are cough syrups indicated for the temporary relief of symptoms occurring with cold or flu, hay fever, or other respiratory allergies. This recall covers only the following lots:

Product Lot Number Expiry Date
ROBITUSSIN HONEY CF MAX
DAY ADULT 4OZ
T10810 31OCT2025
ROBITUSSIN HONEY CF MAX
DAY ADULT 8OZ
T08730
T08731
T08732
T08733
T10808
31MAY2025
31MAY2025
31MAY2025
31MAY2025
30SEP2025
ROBITUSSIN HONEY CF MAX
NT ADULT 8OZ
T08740 T08742 30JUN2026
30JUN2026

Haleon is notifying its distributors and customers directly and has provided them with instructions for the return of all recalled products. Consumers that have purchased the product listed should stop consumption immediately. Please call our Consumer Relations team at +1-800-245-1040 (Monday through Friday 8:00 am – 6:00 pm Eastern Time) or reach out via email.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

  • Complete and submit the report online
  • Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.